Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)

NCT06629779 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06629779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06629779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Recruiting
Start date
October 22, 2024
Completion date
November 30, 2028
Enrollment
900 (estimated)
Sites
231

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer